Difluprednate
Active ingredient: Difluprednate
In short: Difluprednate ophthalmic emulsion is indicated for the treatment of inflammation and pain associated with ocular surgery. Difluprednate ophthalmic emulsion is indicated for the treatment of endogenous anterior uveitis.
What is Difluprednate used for?
Difluprednate ophthalmic emulsion is indicated for the treatment of inflammation and pain associated with ocular surgery.
Difluprednate ophthalmic emulsion is indicated for the treatment of endogenous anterior uveitis.
Difluprednate dosage
Instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.
Instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.
The initial prescription and renewal of the medication order beyond one bottle should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be reevaluated.
Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation.
How to take Difluprednate — instructions & advice from the label
When to Consult a Physician
Advise patients to consult a physician if pain develops, or if redness, itching, or inflammation becomes aggravated .
Risk of Contamination
Advise patients to not allow the dropper tip to touch the eye, eyelids, or any surface, as this may contaminate the ophthalmic emulsion.
Contact Lens Wear
Advise patients to not use difluprednate ophthalmic emulsion while wearing contact lenses. Advise patients to remove contact lenses prior to instillation of difluprednate ophthalmic emulsion. Lenses may be reinserted after 10 minutes following administration of difluprednate ophthalmic emulsion .
Manufactured by
Alcon Laboratories, Inc.
Fort Worth, Texas 76134 for
Sandoz Inc., Princeton, NJ 08540
Warnings & precautions
Do not take this medicine if: Difluprednate ophthalmic emulsion, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. If difluprednate ophthalmic emulsion is used for 10 days or longer, IOP should be routinely monitored.
The use of corticosteroids may result in posterior subcapsular cataract formation.
The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.
Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe.
Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. …
Difluprednate side effects
The following serious reactions are found elsewhere in the labeling:
•Intraocular Pressure ( IOP) Increase
•Cataracts
•Delayed Healing
•Corneal and Scleral Melting
•Bacterial Infections
•Viral Infections
•Fungal Infections
Ocular adverse reactions occurring in 5% to 15% of subjects in clinical studies with difluprednate ophthalmic emulsion included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1% to 5% of subjects, included reduced visual acuity, punctate keratitis, eye inflammation, and iritis. Ocular adverse reactions occurring in less than 1% of subjects, included application-site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritus, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis. Most of these reactions may have been the consequence of the surgical procedure.
A total of 200 subjects participated in the clinical trials for endogenous anterior uveitis, of which 106 were exposed to difluprednate ophthalmic emulsion. …
About this medicine
Difluprednate ophthalmic emulsion, 0.05% is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. The chemical name is 6α,9difluoro-11β,17,21-trihydroxypregna-1,4- diene-3,20-dione 21-acetate 17-butyrate (CAS number 23674-86-4). Difluprednate is represented by the following structural formula:
Difluprednate has a molecular weight of 508.56 g/mol, and the empirical formula is C27H34F2O7.
Each mL of difluprednate ophthalmic emulsion contains:
Active: difluprednate 0.5 mg (0.05%);
Inactives: boric acid, castor oil, edetate disodium, glycerin, polysorbate 80, sodium acetate, sodium hydroxide (to adjust the pH to 5.2 to 5.8), water for injection. Preservative: sorbic acid 0.1%.
The emulsion is essentially isotonic with a tonicity of 304 to 411 mOsm/kg.
How it works: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0f60b857-7898-4a9e-935c-a9ddf0eb9194. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine